. Nomograms constructed using overall survival-related clinical factors and JAK2, STAT5A and STAT6 in two cohorts. Nomograms constructed using overall survival-related clinical factors and genes in (A) the GSE14520 cohort and (B) The Cancer Genome Atlas (B) cohort. AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; JAK, Janus kinase; STAT, signal transducer and activator of transcription; HBV, hepatitis B. Figure S4 . Enriched Gene Ontology terms of key genes of the JAK/STAT pathway. (A) Biological process, (B) cellular component and (C) molecular function. JAK, Janus kinase; STAT, signal transducer and activator of transcription. Figure S4 . Continued. Figure S5 . Schematic of the JAK/STAT signaling pathway. JAK, Janus kinase; STAT, signal transducer and activator of transcription; GF, growth factor; ECS, elongin-cullin-SOCS; p, phosphorylation; TC-PTP, T-cell protein tyrosine phosphatase; SHP1, tyrosine-protein phosphatase non-receptor type 6; STAM, signal-transducing adapter molecules; SHP2, protein tyrosine phosphatase non-receptor type 11; GRB, growth factor receptor bound protein; SOS, son of sevenless; IRF9, interferon regulatory factor 9; MAPK, mitogen-activated protein kinase; CBP/P300, Cbp/P300 interacting transactivator With Glu/Asp rich carboxy-terminal domain; PIAS, protein inhibitor of activated STAT; u, ubiquitination; SLIM, PDZ And LIM domain 2; CIS, cytokine-inducible SH2 protein; AOX, acyl-CoA oxidase; GFAP, glial fibrillary acidic protein; SOCS, suppressor of cytokine signaling; MCL1, myeloid cell leukemia 1; PIM1, Pim-1 proto-oncogene, serine/threonine kinase; CycD, cyclin D. Figure S6 . mRNA expression analysis of 21 pairs of hepatitis B virus-related tumor and non-tumor tissues. (A) JAK2, (B) STAT5A and (C) STAT6. JAK, Janus kinase; STAT, signal transducer and activator of transcription. Table SI . Demographic characteristics of hepatocellular carcinoma patients in the GSE14520 dataset. Overall survival  ----------------------------------------------------------------------------------------------------------------------------------------------- 
